Association between risk-reducing surgeries and survival in young BRCA carriers with breast cancer: an international cohort study.
AuteursBlondeaux E, Sonnenblick A, Agostinetto E, Bas R, Kim HJ, Franzoi MA, Bernstein-Molho R, Linn S, Kwong A, Pogoda K, Balmana J, Smeets A, Bajpai J, Moore HCF, Partridge AH, Phillips KA, Toss A, Rousset-Jablonski C, Peccatori FA, Renaud T, Ferrari A, Paluch-Shimon S, Mando P, Lee JE, Fruscio R, Cui W, Wong SM, Vernieri C, Ruddy KJ, Dieci MV, Matikas A, Rozenblit M, Guven DC, Lee M, Villarreal-Garza C, Hwang SE, De Marchis L, Puglisi F, Kemp Z, Meireles PA, Parokonnaya A, Werutsky G, Okano M, Azim HA, Mati K, Rosenberg S, Gelber R, Boni L, Lambertini M
[Adverse effects of new therapeutic approaches in thoracic oncology].
AuteursSammya A, Normand C, Desbaillets N, Coskun M, Goudemant C, Mosimann V, Ferahta N, Christofis M, Serena A, Nikolopoulou A, Abdelhamid K, Stamatiou A, Nguyen-Ngoc T, Bouchaab H, Fleury M, Obeid M, Peters S, Mederos N
Tumor-stroma proportion on primary tumor as a prognostic biomarker in advanced ovarian cancer patients receiving chemo-immunotherapy as first-line therapy: analyses from the NeoPembrOV/GINECO phase II randomized trial.
AuteursCollet L, Noël JC, Catteau X, Ardin M, Berthet J, Ghamry-Barrin S, Treilleux I, Bengrine Lefevre L, Martinez M, Rothé F, Sotiriou C, Caux C, Dubois B, Ray-Coquard I, Le Saux O
